[A26-11] Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V
Last updated 06.08.2026
Project no.:
A26-11
Commission:
Commission awarded on 15.02.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adult and paediatric patients 8 years of age and older with stage 2 type 1 diabetes mellitus, to delay the onset of stage 3
- For patients with a family history: added benefit not proven (based on the results of the relevant study)
- For patients without a family history: added benefit not proven (no relevant study)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-11
| Project no. | Title | Status |
|---|---|---|
| A26-73 | Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11 | Commission completed |
| G26-17 | Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Second addendum to Project A26-11 | Commission completed |
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision